Growing Aging Trends Will Fuel TransCon Therapy Adoption
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 16 Analysts
Published
21 Jun 25
Updated
08 Aug 25
AnalystHighTarget's Fair Value
US$301.20
34.2% undervalued intrinsic discount08 Aug
US$198.32
1Y
42.8%7D
3.6%